KEY FINDINGS
The United States infertility testing & treatment market is anticipated to record a CAGR of 12.20% during the forecast years. Factors such as technological advancements in IVF procedures, the increasing rates of infertility, and the surge in middle-age pregnancies, are among the key factors expected to propel the market growth of the country. The base year considered for the market study is 2020, and the estimated period is from 2021 to 2026.
MARKET INSIGHTS
Infertility testing and treatment is widely used across the United States, assisting couples with infertility issues, single mothers, and the LGBT community to procreate. The country’s market growth is significantly influenced by aspects like the surging trend of delayed pregnancies, the mounting success rates of IVF, the rise in infertility, and the increasing disposable income. However, the market in the United States is likely to be restricted by the complications associated with IVF, the high costs, and low awareness.
Several regions in the United States have necessitated infertility treatment coverage. Although specific federal laws to regulate the industry’s reimbursement scenario are not set, the IVF bills are introduced by the government. For instance, in 2009, Tennessee passed a bill redefining reimbursement in donor IVF practices. As per Merck Serono’s fertility report, a standard IVF cycle cost is nearly 50% of an individual’s annual income in the United States. However, the majority of employers and companies have not authorized the compensation of fertility services within individual states. Thus, these factors are set to influence the United States infertility testing & treatment market over the forecast years.
COMPETITIVE INSIGHTS
Leading companies operating in the market are Cook Medical Inc, CooperSurgical, Fujifilm Irvine Scientific, Progyny Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. KEY GROWTH ENABLERS
2.5. KEY CHALLENGES
3. KEY ANALYTICS
3.1. IMPACT OF COVID-19 ON INFERTILITY TESTING & TREATMENT MARKET
3.2. KEY MARKET TRENDS
3.3. PORTER’S FIVE FORCES ANALYSIS
3.3.1. BUYERS POWER
3.3.2. SUPPLIERS POWER
3.3.3. SUBSTITUTION
3.3.4. NEW ENTRANTS
3.3.5. INDUSTRY RIVALRY
3.4. OPPORTUNITY MATRIX
3.5. KEY BUYING CRITERIA
3.5.1. TREATMENT OPTIONS
3.5.2. QUALITY OF MEDICAL PROCEDURES
3.5.3. PRICE OF TREATMENTS
3.5.4. SHIFT TOWARDS MEDICAL TOURISM
3.5.5. REIMBURSEMENT
3.6. REGULATORY FRAMEWORK
3.7. VALUE CHAIN ANALYSIS
3.7.1. RAW MATERIAL PROCUREMENT
3.7.2. MANUFACTURING
3.7.3. SUPPLY LOGISTICS
3.7.4. DISTRIBUTION CHANNELS
3.7.5. END-USERS
4. MARKET BY GENDER
4.1. MALE
4.1.1. MALE INFERTILITY TESTING
4.1.1.1. DNA FRAGMENTATION
4.1.1.2. OXIDATIVE STRESS ANALYSIS
4.1.1.3. SPERM PENETRATION ASSAY
4.1.1.4. COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)
4.1.1.5. SPERM AGGLUTINATION
4.1.1.6. MICROSCOPIC EXAMINATION
4.1.1.7. OTHERS
4.1.2. MALE INFERTILITY TREATMENT
4.1.2.1. MEDICATION
4.1.2.2. ASSISTED REPRODUCTIVE TECHNOLOGY & VARICOCELE SURGERY
4.2. FEMALE
4.2.1. FEMALE INFERTILITY TESTING
4.2.1.1. OVULATION TESTING
4.2.1.2. HYSTEROSALPINGOGRAPHY
4.2.1.3. LAPAROSCOPY
4.2.1.4. TRANSVAGINAL ULTRASOUND
4.2.1.5. OVARIAN RESERVE TESTING
4.2.1.6. HORMONAL LEVEL TESTING
4.2.1.7. OTHERS
4.2.2. FEMALE INFERTILITY TREATMENT
4.2.2.1. IVF WITH ICSI
4.2.2.2. IUI
4.2.2.3. IVF WITHOUT ICSI
4.2.2.4. SURROGACY
4.2.2.5. OTHERS
5. MARKET BY END-USER
5.1. FERTILITY AND SURGICAL CENTERS
5.2. HOSPITALS AND RESEARCH LABORATORIES
5.3. CRYOBANKS
6. COMPETITIVE LANDSCAPE
6.1. KEY STRATEGIC DEVELOPMENTS
6.1.1. MERGERS & ACQUISITIONS
6.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
6.1.3. PARTNERSHIPS & AGREEMENTS
6.2. COMPANY PROFILES
6.2.1. COOPER SURGICAL
6.2.2. COOK MEDICAL INC
6.2.3. EMD GROUP (MERCK KGAA)
6.2.4. ESCO MEDICAL
6.2.5. FUJIFILM IRVINE SCIENTIFIC
6.2.6. VITROLIFE AB
1. COOPER SURGICAL
2. COOK MEDICAL INC
3. EMD GROUP (MERCK KGAA)
4. ESCO MEDICAL
5. FUJIFILM IRVINE SCIENTIFIC
6. VITROLIFE AB
